AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.61
−1.07%Sep 17, 2026, 11:00 UTC
Aquestive Therapeutics resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.
Source:Aug 11, 2026, 20:01 UTC
Aquestive Therapeutics reported its financial results for the second quarter ended June 30, 2026.
Aug 10, 2026, 11:00 UTC
Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm (dibutepinephrine) sublingual film, supporting a planned NDA resubmission to the FDA in Q3 2026.